- Home
- FGEN vs ECOR Comparison
FGEN vs ECOR Comparison
Compare FGEN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- ECOR
- Stock Information
- Founded
- FGEN 1993
- ECOR 2005
- Country
- FGEN United States
- ECOR United States
- Employees
- FGEN N/A
- ECOR N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FGEN Health Care
- ECOR Health Care
- Exchange
- FGEN Nasdaq
- ECOR Nasdaq
- Market Cap
- FGEN 45.1M
- ECOR 40.0M
- IPO Year
- FGEN 2014
- ECOR 2018
- Fundamental
- Price
- FGEN $11.12
- ECOR $5.04
- Analyst Decision
- FGEN Strong Buy
- ECOR Strong Buy
- Analyst Count
- FGEN 2
- ECOR 2
- Target Price
- FGEN $146.50
- ECOR $25.50
- AVG Volume (30 Days)
- FGEN 24.8K
- ECOR 41.6K
- Earning Date
- FGEN 11-03-2025
- ECOR 11-05-2025
- Dividend Yield
- FGEN N/A
- ECOR N/A
- EPS Growth
- FGEN N/A
- ECOR N/A
- EPS
- FGEN N/A
- ECOR N/A
- Revenue
- FGEN $7,346,000.00
- ECOR $27,700,000.00
- Revenue This Year
- FGEN N/A
- ECOR $23.74
- Revenue Next Year
- FGEN N/A
- ECOR $42.02
- P/E Ratio
- FGEN N/A
- ECOR N/A
- Revenue Growth
- FGEN N/A
- ECOR 30.16
- 52 Week Low
- FGEN $4.50
- ECOR $4.16
- 52 Week High
- FGEN $21.94
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- FGEN 50.35
- ECOR 50.60
- Support Level
- FGEN $10.59
- ECOR $4.88
- Resistance Level
- FGEN $11.22
- ECOR $5.19
- Average True Range (ATR)
- FGEN 0.52
- ECOR 0.23
- MACD
- FGEN -0.00
- ECOR 0.01
- Stochastic Oscillator
- FGEN 58.60
- ECOR 59.91
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.